OptimizeRx Corp.

OPRX Healthcare Health Information Services

OptimizeRx Corp.’s revenue for fiscal 2025 (year ended December 2025) was $109.4 million, up 18.8% from fiscal 2024. In the quarter to June 2026, revenue fell 29.8%, EPS fell 150.0%, free cash flow grew 89.9% and total debt fell 33.1%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

8.50 0.35 −3.95%
Market cap
$166.7M
P/E
35.4×
Fwd P/E
23.0×
Dividend yield
—
F-score
8/9
Altman Z
3.31
Beneish M
−2.77
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 45.41 17.44 23.83
P/S ratio
3.48 2.08 1.10 1.09
P/FCF ratio
32.93 12.11 8.12 5.79
P/Operating CF
118.93 32.09 (252.30) 12.48
P/B ratio
3.11 1.77 0.91 0.82
EV/Sales
3.56 2.10 1.13 1.04
EV/EBITDA
82.57 13.41 6.12 6.27
EV/FCF
33.68 12.24 8.34 5.51
Current Ratio
3.05 3.04 5.37 5.58
Net Debt/EBITDA
2.60 0.23 1.75 (4.06)
Debt/Equity
0.23 0.20 0.18 0.15
Earnings Yield
0.00% 2.20% 5.73% 4.20%
Free Cash Flow Yield
3.04% 8.26% 12.32% 17.28%
Free Cash Flow per Share
0.17 0.39 (0.03) 0.46
Book value per Share
6.58 6.91 6.91 6.98
Free Cash Flow
3.19 7.29 (0.49) 8.58
EV/EBIT
57.36 19.65 8.53 9.39
Other line items

Show all line items

Columns are period end dates